{"id":908464,"date":"2025-11-11T09:50:49","date_gmt":"2025-11-11T14:50:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/"},"modified":"2025-11-11T09:50:49","modified_gmt":"2025-11-11T14:50:49","slug":"new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/","title":{"rendered":"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>By 2045, incretin-based drugs such as GLP-1s could reduce mortality in the US by 3.5% in a central scenario, 8.8% in an optimistic scenario, and 1.0% in a pessimistic scenario.\u00a0<\/i><\/li>\n<li><i>Under the same central scenario, mortality could decrease by 2.0% in the UK, 2.6% in Canada, and 1.4% in Hong Kong.\u00a0<\/i><\/li>\n<li><i>Mortality improvements will vary by age, with ages 45-59 seeing the biggest reduction and age 85+ the lowest reduction.<\/i><\/li>\n<\/ul>\n<p>ST. LOUIS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rgare.com%2F&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=Reinsurance+Group+of+America%2C+Incorporated&amp;index=1&amp;md5=2d3c7776c48258109e552ea91f855507\">Reinsurance Group of America, Incorporated<\/a> (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity impacts of incretin-based therapies, including GLP-1s, approved as anti-obesity medications (AOMs) and diabetes treatments. The study examined data from four markets (US, UK, Canada, and Hong Kong) to assess how widespread adoption of AOMs could affect population health outcomes over the next two decades. Key findings are published in the full report, \u201c<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F3JpMZzK&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=Weighing+the+Evidence%3A+A+quantification+of+the+mortality+and+morbidity+impacts+of+GLP-1+and+other+incretin-based+drugs+in+the+US%2C+UK%2C+Canada%2C+and+Hong+Kong+populations&amp;index=2&amp;md5=a292f8ab98c00a85d060255ccf7248bd\">Weighing the Evidence: A quantification of the mortality and morbidity impacts of GLP-1 and other incretin-based drugs in the US, UK, Canada, and Hong Kong populations<\/a>.\u201d<\/p>\n<p>\nBased on RGA\u2019s models, AOMs have the potential to meaningfully improve population mortality and disease incidence rates and could reduce mortality in the US by 3.5% by 2045 in a central scenario. RGA\u2019s research models the impact of AOMs over the next 20 years to 2045 using three key groups of assumptions: effectiveness, uptake, and relative risk of mortality and morbidity. In addition to a central scenario, the research calculates optimistic and pessimistic scenarios by flexing these key assumptions to plausible higher and lower values.<\/p>\n<p><b>Key findings:<\/b><\/p>\n<p><b>Population mortality<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nBy 2045, incretin-based drugs such as GLP-1s could reduce mortality in the US by 3.5% in a central scenario, 8.8% in an optimistic scenario, and 1.0% in a pessimistic scenario.<\/p>\n<\/li>\n<li>\nUnder the same central scenario, mortality could decrease by 2.0% in the UK, 2.6% in Canada, and 1.4% in Hong Kong.<\/p>\n<\/li>\n<li>\nMortality improvements will vary by age, with ages 45-59 seeing the biggest reduction and age 85+ the lowest reduction.<\/p>\n<\/li>\n<\/ul>\n<p><b>Population morbidity<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPopulations could see smaller but still positive reductions in the incidence of cancers over the same period.<\/p>\n<\/li>\n<\/ul>\n<p><b>Insured mortality and morbidity<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nInsured groups and annuitants are likely to see somewhat lower mortality and morbidity reductions than the general population.<\/p>\n<\/li>\n<\/ul>\n<p>\n\u201cWe believe that anti-obesity medications will have a meaningful benefit on general population-level mortality. This will differ by geography, largely reflecting the obesity profiles of different markets, and by age, sex, and access to medicines,\u201d said Tony Cheng, President and CEO, RGA. \u201cFor insured groups, we tend to observe a lower average BMI, which is likely to translate to a smaller overall mortality impact compared to the general population.\u201d<\/p>\n<p>\nAlthough cost remains an obstacle to wider use, growing competition and the arrival of generic and oral formulations are expected to lower prices. The next wave of incretin-based therapies is poised to offer significant advantages over the current generation for treating diabetics and supporting weight loss in those living with obesity.<\/p>\n<p>\nIncretin-based therapies are under active investigation to treat a growing spectrum of medical conditions ranging from neurodegenerative disorders to substance abuse. There is also increasing interest in their potential for disease prevention due to the demonstrated systemic anti-inflammatory properties, metabolic regulatory effects, and the ability to influence satiety and insulin sensitivity.<\/p>\n<p>\n\u201cThis is a fast-moving space with significant uncertainty, but the potential of these drugs is exciting,\u201d added Cheng. \u201cAs the list of approved indications continues to expand, and adoption rises among those with existing illnesses, these therapies hold the potential to deliver a substantial positive impact on public health.\u201d<\/p>\n<p>\nFor more detailed information, view the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F3JpMZzK&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=full+research+report&amp;index=3&amp;md5=8f7fb2ff922df42ad03adcc9480f1989\">full research report<\/a>. For RGA\u2019s perspective on how insurers can best reflect medical advancements, such as GLP-1 drugs in forward-looking biometric assumptions, read the companion paper, \u201c<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rgare.com%2Fdocs%2Fdefault-source%2Fknowledge-center-articles%2Fevaluating-biometric-trend-drivers.pdf%3Fsfvrsn%3Dbfe2e693_7&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=Evaluating+Biometric+Trend+Drivers%3A+How+to+reflect+medical+breakthroughs+and+other+drivers+in+forward-looking+assumptions&amp;index=4&amp;md5=fa12f60aeb87c96129b08c24a5ffbe1f\">Evaluating Biometric Trend Drivers: How to reflect medical breakthroughs and other drivers in forward-looking assumptions<\/a>.\u201d<\/p>\n<p><b>About RGA<\/b><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F3TH2d5u&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=Reinsurance+Group+of+America%2C+Incorporated&amp;index=5&amp;md5=7dea22d50a737af34bd85595ec8b06d8\">Reinsurance Group of America, Incorporated<\/a> (NYSE: RGA) is a global industry leader specializing in life and health reinsurance and financial solutions that help clients effectively manage risk and optimize capital. Founded in 1973, RGA is one of the world\u2019s largest and most respected reinsurers and remains guided by a powerful purpose: to make financial protection accessible to all. As a global capabilities and solutions leader, RGA empowers partners through bold innovation, relentless execution, and dedicated client focus \u2014 all directed toward creating sustainable long-term value. RGA has approximately $4.3 trillion of life reinsurance in force and total assets of $152.0 billion as of September 30, 2025. To learn more about RGA and its businesses, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rgare.com%2F&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=rgare.com&amp;index=6&amp;md5=9389c758cf948f6ba0d36dd508a04f15\">rgare.com<\/a> or follow RGA on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F3Vqp4DE&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=caac9650c1652ccb5aa441c6f83f85d0\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F3wRrgtB&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=09b6b9760ab3e40c8b04fe64e98c7f85\">Facebook<\/a>. Investors can learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F3VmAAjk&amp;esheet=54355821&amp;newsitemid=20251111928048&amp;lan=en-US&amp;anchor=investor.rgare.com&amp;index=9&amp;md5=5e7d52b7c18fa128fe67d8a7faccff90\">investor.rgare.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251111928048\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251111928048\/en\/<\/a><\/span><\/p>\n<p>\nRGA<br \/>\n<br \/>Lynn Phillips<br \/>\n<br \/>Senior Vice President, Enterprise Marketing &amp; Communications<br \/>\n<br \/>636-736-2351<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lphillips@rgare.com\">lphillips@rgare.com<br \/>\n<\/a><\/p>\n<p>Lizzie Curry\u00a0<br \/>\n<br \/>Executive Director, Public Relations<br \/>\n<br \/>636-736-8521<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lizzie.curry@rgare.com\">lizzie.curry@rgare.com<br \/>\n<\/a><\/p>\n<p>Eli Schneiders<br \/>\n<br \/>Manager, Public Relations<br \/>\n<br \/>314.439.6706<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Eli.Schnieders@rgare.com\">Eli.Schnieders@rgare.com<br \/>\n<\/a><\/p>\n<p>Jeff Hopson<br \/>\n<br \/>Senior Vice President, Investor Relations<br \/>\n<br \/>636-736-2068<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jhopson@rgare.com\">jhopson@rgare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Missouri United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Other Health General Health Professional Services Pharmaceutical Fitness &amp; Nutrition Health Insurance Science Insurance Finance Vitamins\/Supplements Health Diabetes<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251111928048\/en\/2014893\/3\/RGA_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years By 2045, incretin-based drugs such as GLP-1s could reduce mortality in the US by 3.5% in a central scenario, 8.8% in an optimistic scenario, and 1.0% in a pessimistic scenario.\u00a0 Under the same central scenario, mortality could decrease by 2.0% in the UK, 2.6% in Canada, and 1.4% in Hong Kong.\u00a0 Mortality improvements will vary by age, with ages 45-59 seeing the biggest reduction and age 85+ the lowest reduction. ST. LOUIS&#8211;(BUSINESS WIRE)&#8211;Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity impacts of incretin-based therapies, including GLP-1s, approved as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908464","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years By 2045, incretin-based drugs such as GLP-1s could reduce mortality in the US by 3.5% in a central scenario, 8.8% in an optimistic scenario, and 1.0% in a pessimistic scenario.\u00a0 Under the same central scenario, mortality could decrease by 2.0% in the UK, 2.6% in Canada, and 1.4% in Hong Kong.\u00a0 Mortality improvements will vary by age, with ages 45-59 seeing the biggest reduction and age 85+ the lowest reduction. ST. LOUIS&#8211;(BUSINESS WIRE)&#8211;Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity impacts of incretin-based therapies, including GLP-1s, approved as &hellip; Continue reading &quot;New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T14:50:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years\",\"datePublished\":\"2025-11-11T14:50:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/\"},\"wordCount\":881,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/\",\"name\":\"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-11-11T14:50:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/","og_locale":"en_US","og_type":"article","og_title":"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years - Market Newsdesk","og_description":"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years By 2045, incretin-based drugs such as GLP-1s could reduce mortality in the US by 3.5% in a central scenario, 8.8% in an optimistic scenario, and 1.0% in a pessimistic scenario.\u00a0 Under the same central scenario, mortality could decrease by 2.0% in the UK, 2.6% in Canada, and 1.4% in Hong Kong.\u00a0 Mortality improvements will vary by age, with ages 45-59 seeing the biggest reduction and age 85+ the lowest reduction. ST. LOUIS&#8211;(BUSINESS WIRE)&#8211;Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity impacts of incretin-based therapies, including GLP-1s, approved as &hellip; Continue reading \"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-11T14:50:49+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years","datePublished":"2025-11-11T14:50:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/"},"wordCount":881,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/","name":"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-11-11T14:50:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251111928048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-research-from-rga-glp-1s-expected-to-reduce-us-mortality-by-3-5-over-the-next-20-years\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908464"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908464\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}